⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

April 17, 2012Current Opinion in Lipidology

Apolipoprotein C-III and hepatic triglyceride-rich lipoprotein production

View Full Paper

Ask AI

Bookmark

Share

Design

Review

Authors

ZYZemin YaoChina Academy of Space Technology YWYuwei WangZhejiang University

Discussion

Loading...

Member takes

Implication

May support apo C-III inhibition in diabetic hypertriglyceridemia; leaves open clinical validation of intrahepatic mechanisms.

Key Points

Key points are not available for this paper at this time.

Cite This Study

Yao et al. (2012) studied this question.

synapsesocial.com/papers/6a718ca28031ec7bb1dd04d8 https://doi.org/10.1097/mol.0b013e328352dc70

View Full Paper

Ask AI

Bookmark

Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Apolipoprotein C-III(Lys58----Glu). Identification of an apolipoprotein C-III variant in a family with hyperalphalipoproteinemia.1991 · 81 citations
2Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease2005 · 3,561 citations
3Structure and Dynamics of Human Apolipoprotein CIII2008 · 91 citations
4A Null Mutation in Human APOC3 Confers a Favorable Plasma Lipid Profile and Apparent Cardioprotection2008 · 699 citations
5Glucose-stimulated insulin secretion suppresses hepatic triglyceride-rich lipoprotein and apoB production2000 · 88 citations